http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Hong Yu Appointed President of Biostage
-
Dr. Wei Zhang Elected to Biostage's Board of Directors
-
Biostage Reports 2018 First Quarter Financial Results
-
Biostage to Host Conference Call to Discuss First Quarter 2018 Financial Results and Operations
-
Biostage Reports 2017 Financial Results
-
Biostage Names Distinguished Children's Hospital Executive James Shmerling to its Board of Directors
-
Biostage awarded SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for esophageal atresia in pediatric patients
-
Biostage Preclinical Study Results Published in New Report
-
Biostage Closes $1 Million Private Placement
-
Biostage Appoints to its Scientific Advisory Board Charles S. Cox, Jr., MD
-
Biostage, Inc. Names Jason Chen Chairman of its Board of Directors
-
Biostage to Host Conference Call to Provide Business Update
-
Biostage Appoints to its Scientific Advisory Board Christine Finck, MD, Executive Vice President, Surgeon-in-Chief at Connecticut Children's Medical Center
-
Biostage Closes $4.2 Million Private Placement
-
Biostage Announces Reverse Stock Split Effective December 22, 2017
-
Biostage Announces Binding Agreement For $4.0 Million Private Placement
-
Biostage Conducts Reduction In Force, Evaluating Strategic Alternatives
-
Biostage (BSTG) to Move from Nasdaq to OTCQB Marketplace
-
Biostage to Move to OTCQB Marketplace
-
Biostage to Present at the 2017 Cell & Gene Meeting on the Mesa
-
Biostage Reports 2017 Second Quarter Financial Results:
-
Biostage (BSTG) Reports Use of Its Esophageal Implant Product Candidate
-
Biostage Announces the Use of Its Esophageal Implant Product Candidate in a Patient
-
Biostage to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Business Update
-
Biostage (BSTG) Granted Continued Listing on Nasdaq
-
Biostage Granted Continued Listing on Nasdaq
-
Biostage Announces Agreement to Conduct $3.1 Million Private Placement at Market
-
Biostage (BSTG) Says Positive Preclinical Data of Cellspan Esophageal Implant Presented at ISSCR
-
Biostage Announces Positive Preclinical Data of Cellspan™ Esophageal Implant Presented at the International Society for Stem Cell Research 2017 Annual Meeting
-
Biostage to Present at the 2017 Marcum MicroCap Conference
-
Biostage to Present at the Cell and Gene Exchange 2017
-
Biostage (BSTG) Receives Nasdaq Listing Determination; Plans to Request Hearing
-
Biostage Announces Receipt of Nasdaq Listing Determination
-
Biostage Reports 2017 First Quarter Financial Results and Provides Business Update
-
Dr. Christine Finck of Connecticut Children's Medical Center, Presents Data in Poster Presentation from Collaboration with Biostage at the American Pediatric Surgical Association (APSA) 2017 Annual Me
-
Biostage to Host 2017 First Quarter Update Conference Call
-
Biostage to Present at the American Association for Thoracic Surgery Centennial Meeting
-
Biostage to Participate at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day
-
Biostage Appoints Stephen F. Badylak DVM, PhD, MD, as Co-Chairman of Scientific Advisory Board
-
Biostage (BSTG) Highlights Positive Preclincal Data of Cellspan Esophageal Implant at Society For Biomaterials 2017 Conference
-
Biostage Presents Positive Preclincal Data of Cellspan Esophageal Implant at Society For Biomaterials 2017 Annual Meeting and Exposition
-
Biostage to Participate at the MassBio 2017 Annual Meeting
-
Biostage Promotes Saverio La Francesca, M.D. to President
-
Biostage Reports 2016 Financial Results and Provides Business Update
-
Biostage to Host Fiscal Year 2016 Update Conference Call
-
Biostage to Present at Biotech Showcase™ 2017
-
Biostage to Participate at the 2016 World Stem Cell Summit and RegMed Capital Conference
-
Biostage (BSTG) Granted Orphan Drug Status for Cellspan Esophageal Implant
-
Biostage Receives FDA Orphan Drug Designation for Cellspan™ Esophageal Implant
-
Nasdaq Provides Biostage with 180-day Period in Which to Regain Compliance with $1.00 Minimum Closing Bid Price Rule

